This article is more than 5 years old. Information may no longer be current.

Allergan acquires AqueSys, adds Xen45 to pipeline

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Allergan has completed the acquisition of AqueSys in an all-cash transaction, according to a press release.

The acquisition includes a $300 million up-front payment and potential regulatory approval and commercialization milestone payments related to Xen45, a minimally invasive implantable shunt to reduce IOP in patients with glaucoma.

“The acquisition of AqueSys and Xen45 is highly complementary to our leadership position in eye care and underscores our commitment to develop and commercialize treatments that advance care and add value for ophthalmologists and their patients,” Brent Saunders, CEO and president of Allergan, said in the release.

Xen45 has a CE mark in the European Union. It is in late-stage development in the U.S., with 510(k) clearance expected in late 2016 or early 2017.